Restriction endonucleases market seen reaching $1.1 billion by 2030

The global restriction endonucleases product market is projected to rise from $0.73 billion in 2025 to $0.79 billion in 2026, with the research firm forecasting $1.1 billion by 2030. Growth is tied to genomics research, personalized medicine, gene-editing adoption and demand for precision DNA tools.

Why it matters: - Restriction endonucleases are core tools for DNA cutting, cloning, sequencing, genome mapping and gene editing. - Demand rises when genomics, biotech R&D and personalized medicine programs expand. - The market’s growth points to continued spending on the lab technologies that support precision medicine and synthetic biology.

What happened: - The Business Research Company published its Restriction Endonucleases Product Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Sept. 22, 2026. - The report says the market will grow from $0.73 billion in 2025 to $0.79 billion in 2026. - The report forecasts the market will reach $1.1 billion by 2030. - The report places North America as the largest market in 2025. - The report expects Asia-Pacific to be the fastest-growing region during the forecast period. - Download a free sample of the report. - View the full market report.

The details: - The report says the market’s 2025-2026 growth reflects an 8.9% CAGR. - The forecast period points to an 8.4% CAGR through 2030. - The report links historical growth to molecular biology research, biotech and pharma R&D, DNA cloning, recombinant enzyme production and academic genetics investment. - The report links future growth to precision medicine, genomics applications, gene-editing adoption, personalized medicine pipelines, high-throughput sequencing workflows and synthetic biology tools. - Restriction endonucleases identify and cut DNA at specific sequences. - The enzymes are used in molecular biology and genetic engineering to support cloning, sequencing, genome mapping, gene editing and nucleic acid manipulation. - The report says manufacturing requires tight controls to preserve specificity, activity, stability and reliability in research and diagnostic use. - Genomics research is a key demand driver because it helps researchers study gene function, variation, disease mechanisms and biological processes. - Sequencing advances have made genome analysis more accessible and precise. - NHS England’s Genomic Medicine Service completed more than 810,000 genomic tests across all age groups in England in February 2025, up 8% from the previous year. - Personalized medicine is another growth driver because treatment selection increasingly depends on genetic profile. - Precision medicine relies on genomics and biotechnology to improve diagnostics and targeted therapies. - The Personalized Medicine Coalition reported in February 2024 that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from 6 in 2022. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The market forecast reflects a broader shift toward workflows that depend on exact DNA manipulation rather than broad, one-size-fits-all lab methods. - North America’s lead suggests mature research infrastructure and biotech density still anchor current demand. - Asia-Pacific’s expected growth suggests the next wave of demand may come from expanding genomics capacity and gene-editing adoption.

What's next: - Demand should track the pace of genomics testing, precision medicine pipelines and gene-editing research. - Growth in sequencing, synthetic biology and DNA engineering tools should keep restriction endonucleases embedded in core lab workflows. - The Business Research Company says its 2026 reports also include market attractiveness scoring, TAM analysis, company scoring matrices, forecasting dashboards, hotspot infographics and future trend analysis.

The bottom line: - Restriction endonucleases remain a small but expanding market tied to some of biotech’s fastest-growing research areas, with the report projecting steady gains through 2030.